Intellia Therapeutics News - June 2026
🟢 Intellia Therapeutics Inc is trading 5.84% up today as it extends gains from positive CRISPR trial data
Intellia Therapeutics Inc is trading at $15.40 (+5.84%) today, extending a sharp upward move sparked by recent positive CRISPR trial data. • The stock...
🟢 Intellia Therapeutics Inc is trading 10.2% up today after positive Phase 3 HAELO trial results for HAE therapy
Intellia Therapeutics Inc is trading 10.2% up at $13.35 after releasing additional positive Phase 3 HAELO trial results for its hereditary angioedema...
Intellia Reports Positive Phase 3 Trial Results for HAE Therapy Lonvo-z
Intellia Therapeutics announced additional positive results from its global Phase 3 HAELO clinical trial for lonvoguran ziclumeran (lonvo-z), a single-dose...
🟢 Intellia Therapeutics Inc is trading 5% up today after positive Phase 3 HAELO trial results for lonvo-z
Intellia Therapeutics Inc is trading 5% up at $12.72 in pre-market, rebounding after recent weakness following the disclosure of positive clinical data. • The...
Intellia Reports 87% Drop in HAE Attacks, Meeting Phase 3 Endpoints
Intellia Therapeutics announced positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema (HAE). The European Academy...